Rapport Therapeutics (RAPP) CEO Abraham Ceesay sells 51,499 shares via 10b5-1 plan

Rhea-AI Filing Summary

Rapport Therapeutics, Inc. Chief Executive Officer Abraham Ceesay reported open-market sales of 51,499 shares of common stock on August 10–11, 2026, in multiple transactions at weighted average prices between about $45.97 and $48.62. The sales were effected pursuant to Rule 10b5-1 trading plans adopted on March 27, 2026. Following these trades, indirect holdings include 81,729 shares held by the Ceesay Family Irrevocable Trust and 20,729 shares held by the Dorothy Ceesay Irrevocable Trust.

Insider Trade Summary 10b5-1

Net Seller: 51,499 shares

Net Sell 7 txns

Insider Ceesay Abraham

Role Chief Executive Officer

Sold 51,499 shs ($2.43M)

Type	Security	Shares	Price	Value
Sale	Common Stock F1, F4	3,664	$46.8988	$172K
Sale	Common Stock F1, F5	19,500	$48.0434	$937K
Sale	Common Stock F1, F6	5,794	$48.6229	$282K
Sale	Common Stock F1, F2	14,171	$45.9736	$651K
Sale	Common Stock F1, F3	8,370	$46.7479	$391K
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 486,108 shares (Direct); Common Stock — 81,729 shares (Indirect, By Ceesay Family Irrevocable Trust); Common Stock — 20,729 shares (Indirect, By Dorothy Ceesay Irrevocable Trust)

Footnotes (6)

1. F1. These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on March 27, 2026.
2. F2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $45.37 to $46.36, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
3. F3. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $46.38 to $47.01, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
4. F4. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $46.32 to $47.29, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
5. F5. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $47.45 to $48.43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
6. F6. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $48.45 to $48.87, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.

Key Figures

Total shares sold: 51,499 shares Sale block: 14,171 shares at $45.9736 per share Sale block: 8,370 shares at $46.7479 per share +5 more

8 metrics

Total shares sold 51,499 shares Aggregate non-derivative common stock sales on August 10–11, 2026

Sale block 14,171 shares at $45.9736 per share Common stock sale on August 10, 2026

Sale block 8,370 shares at $46.7479 per share Common stock sale on August 10, 2026

Sale block 3,664 shares at $46.8988 per share Common stock sale on August 11, 2026

Sale block 19,500 shares at $48.0434 per share Common stock sale on August 11, 2026

Sale block 5,794 shares at $48.6229 per share Common stock sale on August 11, 2026

Ceesay Family Irrevocable Trust holdings 81,729 shares Indirect ownership entry dated August 10, 2026

Dorothy Ceesay Irrevocable Trust holdings 20,729 shares Indirect ownership entry dated August 10, 2026

Key Terms

Rule 10b5-1 trading plans, weighted average price, indirect ownership, irrevocable trust

4 terms

Rule 10b5-1 trading plans regulatory

"These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans"

Rule 10b5-1 trading plans are written, pre-arranged instructions that allow company insiders (such as executives or directors) to automatically buy or sell their company's stock at specified times or under set conditions, like a standing instruction or automated thermostat for trades. They matter to investors because these plans provide a legal defense against insider‑trading accusations and create predictable insider trading patterns that can help signal whether sales are routine portfolio management or potentially meaningful to the company’s outlook.

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

indirect ownership financial

"ownership_type": "indirect", "nature_of_ownership": "By Ceesay Family Irrevocable Trust""

irrevocable trust financial

"nature_of_ownership": "By Dorothy Ceesay Irrevocable Trust""

An irrevocable trust is a legal arrangement where an owner transfers assets into a separate entity managed by a trustee and gives up the power to modify or reclaim those assets. For investors it matters because putting stock or other holdings into such a trust can change who controls and benefits from the assets, affect taxes and creditor protection, and influence how easy it is to sell or value those holdings—like placing valuables in a locked safe overseen by someone else.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/12/2026 - 04:36 PM Accepted by SEC EDGAR 08/12/2026 - 04:35 PM Learn about SEC filing dates

FAQ

What did Rapport Therapeutics (RAPP) CEO Abraham Ceesay report in this Form 4?

Abraham Ceesay reported open-market sales of 51,499 shares of Rapport Therapeutics common stock on August 10–11, 2026, executed in several transactions at weighted average prices in the mid-$40s per share.

At what prices were the RAPP shares sold by CEO Abraham Ceesay?

The reported sales occurred at weighted average prices including $45.9736, $46.7479, $46.8988, $48.0434, and $48.6229 per share, each representing averages of multiple trades within specified intraday price ranges.

How many Rapport Therapeutics (RAPP) shares did the CEO sell in total?

Abraham Ceesay sold a total of 51,499 shares of Rapport Therapeutics common stock across five reported transactions, according to the Form 4 transaction summary for August 10–11, 2026.

Were the RAPP CEO’s stock sales made under a Rule 10b5-1 trading plan?

Yes. The Form 4 states the transactions were effected pursuant to Rule 10b5-1 trading plans adopted on March 27, 2026, indicating the trades were pre-arranged under that plan framework.

What indirect RAPP shareholdings are reported for Abraham Ceesay after these transactions?

Reported indirect holdings after the transactions include 81,729 shares held by the Ceesay Family Irrevocable Trust and 20,729 shares held by the Dorothy Ceesay Irrevocable Trust, both shown as indirect ownership positions.

How many individual sale transactions did the RAPP CEO report?

The filing lists five non-derivative sale transactions in common stock, all coded as “S” for open-market or private sales, plus two separate holding entries reflecting indirect trust ownership positions.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ceesay Abraham

(Last) (First) (Middle)

RAPPORT THERAPEUTICS, INC.

99 HIGH STREET, SUITE 2100

(Street)

BOSTON MASSACHUSETTS 02110

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Rapport Therapeutics, Inc. [ RAPP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/10/2026		S(1)		14,171	D	$45.9736(2)	523,436	D
Common Stock	08/10/2026		S(1)		8,370	D	$46.7479(3)	515,066	D
Common Stock	08/11/2026		S(1)		3,664	D	$46.8988(4)	511,402	D
Common Stock	08/11/2026		S(1)		19,500	D	$48.0434(5)	491,902	D
Common Stock	08/11/2026		S(1)		5,794	D	$48.6229(6)	486,108	D
Common Stock								81,729	I	By Ceesay Family Irrevocable Trust
Common Stock								20,729	I	By Dorothy Ceesay Irrevocable Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on March 27, 2026.

2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $45.37 to $46.36, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.

3. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $46.38 to $47.01, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.

4. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $46.32 to $47.29, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.

5. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $47.45 to $48.43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.

6. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $48.45 to $48.87, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.

	/s/ Troy Ignelzi, Attorney-in-Fact	08/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)